(Q44826295)

6 December 2017

title

Early response predicts thalidomide efficiency in patients with advanced multiple myeloma (English)

1 reference

6 December 2017

0 references

Anders Waage

1

1 reference

6 December 2017

Peter Gimsing

2

1 reference

6 December 2017

Gunnar Juliusson

3

1 reference

6 December 2017

Ingemar Turesson

4

1 reference

6 December 2017

Nina Gulbrandsen

5

1 reference

6 December 2017

Tommy Eriksson

6

1 reference

6 December 2017

Martin Hjorth

7

1 reference

6 December 2017

Johan Lanng Nielsen

8

1 reference

6 December 2017

Stig Lenhoff

9

1 reference

6 December 2017

Jan Westin

10

1 reference

6 December 2017

Finn Wislöff

11

1 reference

6 December 2017

Nordic Myeloma Study Group

12

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

British Journal of Haematology

6 December 2017

published in

1 reference

6 December 2017

volume

125

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

149-155

1 reference

Thalidomide and dexamethasone for resistant multiple myeloma

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Thalidomide in multiple myeloma: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Clinical pharmacology of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Thalidomide: emerging role in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Thalidomide treatment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04879.X

10.1111/J.1365-2141.2004.04879.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference